CardioMEMS expands intrasac pressure instrument to US TAA (thoracic aortic aneurysm) market:
This article was originally published in Clinica
Executive Summary
Extending the market of its EndoSure pressure-measuring system beyond use in aortic aneurysm repair, CardioMEMS has gained US clearance to also use the wireless product during thoracic aortic aneurysm (TAA) repair. The device, designed to measure vital medical parameters such as mean pressure, systolic pressure, diastolic pressure, heart rate and cardiac output, is comprised of an implanted sensor and an external electronics module. The EndoSure sensor is inserted during the minimally-invasive cardiovascular repair of an aneurysm via a catheter into the aneurysm sac, where it measures and communicates pressure information to an external electronics module. The information is processed in real time and displayed as a pressure waveform, according to the Atlanta, Georgia firm.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.